{"PubmedArticle": [{"MedlineCitation": {"KeywordList": [["LADA (latent autoimmune diabetes in adults)", "berberine", "diabetes care", "glycemic control", "inulin", "randomized controlled trial"]], "GeneralNote": [], "OtherAbstract": [], "CitationSubset": ["IM"], "SpaceFlightMission": [], "OtherID": [], "InvestigatorList": [], "PMID": "35784546", "DateCompleted": {"Year": "2022", "Month": "07", "Day": "06"}, "DateRevised": {"Year": "2022", "Month": "07", "Day": "28"}, "Article": {"ArticleDate": [{"Year": "2022", "Month": "06", "Day": "15"}], "Language": ["eng"], "ELocationID": ["876657", "10.3389/fendo.2022.876657"], "Journal": {"ISSN": "1664-2392", "JournalIssue": {"Volume": "13", "PubDate": {"Year": "2022"}}, "Title": "Frontiers in endocrinology", "ISOAbbreviation": "Front Endocrinol (Lausanne)"}, "ArticleTitle": "Effects of Berberine Plus Inulin on Diabetes Care in Patients With Latent Autoimmune Diabetes in Adults: Protocol for a Randomized Controlled Trial.", "Pagination": {"StartPage": "876657", "MedlinePgn": "876657"}, "Abstract": {"AbstractText": ["Latent autoimmune diabetes in adults (LADA) is a heterogeneous form of diabetes, characterized by autoimmune destruction of pancreatic \u03b2-cells as well as insulin resistance and is triggered by environmental factors in the context of genetic susceptibility. Berberine (BBR), a small alkaloid isolated from medicinal plants, has antidiabetic, anti-inflammatory, and antibacterial effects. Inulin is a common prebiotic that has been shown to improve glycemic control, alter the gut microbiota and suppress inflammation. The primary purpose of this study was to evaluate the effects of oral BBR and inulin combined with insulin therapy on diabetes care in patients with LADA.", "We will conduct a single-center, prospective, randomized, double-blind, placebo-controlled trial. A total of 240 patients with LADA who have started insulin therapy will be randomly allocated either to the intervention or control group. After a 1-week run-in period, they will complete a 3-month treatment of BBR alone, inulin plus BBR, inulin alone, or placebo. Anthropometric and clinical data will be collected at five time points: baseline, 3 months, 6 months, 9 months, and 12 months from baseline. The primary outcome was the change in glycated hemoglobin levels. Dynamic blood glucose parameters, \u03b2-cell function, and gut microbiota, as well as adverse events and quality of life will be monitored.", "Glycemic control is critical for preventing the progression of diabetes. Although insulin is a recommended treatment for patients with LADA, there are currently no drugs that can effectively prevent the progressive destruction of pancreatic \u03b2-cells or maintain their function. Several studies have found that when berberine and prebiotics are used alone, they have beneficial metabolic effects. This clinical research protocol will assess the efficacy of the combined treatment of berberine plus inulin and provide new ideas for future pharmacological research and clinical practices in diabetes care and glycemic control for LADA patients.", "This study has been approved by the Ethics Committee of National Clinical Research Center of the Second Xiangya Hospital of Central South University (approval number: 2021-046).", "ClinicalTrials.gov, identifier NCT04698330."], "CopyrightInformation": "Copyright \u00a9 2022 Zhang, Xiao, Yan, Yang, Wu, Mei and Zhou."}, "AuthorList": [{"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "National Clinical Research Center for Metabolic Diseases, Key Laboratory of Diabetes Immunology, Ministry of Education, and Department of Metabolism and Endocrinology, The Second Xiangya Hospital of Central South University, Changsha, China."}], "LastName": "Zhang", "ForeName": "Rong", "Initials": "R"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "National Clinical Research Center for Metabolic Diseases, Key Laboratory of Diabetes Immunology, Ministry of Education, and Department of Metabolism and Endocrinology, The Second Xiangya Hospital of Central South University, Changsha, China."}], "LastName": "Xiao", "ForeName": "Yang", "Initials": "Y"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Endocrinology, The First People's Hospital of Pingjiang, Pingjiang, China."}], "LastName": "Yan", "ForeName": "Jianru", "Initials": "J"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Endocrinology, The First People's Hospital of Pingjiang, Pingjiang, China."}], "LastName": "Yang", "ForeName": "Wen", "Initials": "W"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Endocrinology, The First People's Hospital of Pingjiang, Pingjiang, China."}], "LastName": "Wu", "ForeName": "Xiaomei", "Initials": "X"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Anorectal Surgery, Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai, China."}, {"Identifier": [], "Affiliation": "Anorectal Disease Institute of Shuguang Hospital, Shanghai, China."}], "LastName": "Mei", "ForeName": "Zubing", "Initials": "Z"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "National Clinical Research Center for Metabolic Diseases, Key Laboratory of Diabetes Immunology, Ministry of Education, and Department of Metabolism and Endocrinology, The Second Xiangya Hospital of Central South University, Changsha, China."}], "LastName": "Zhou", "ForeName": "Zhiguang", "Initials": "Z"}], "DataBankList": [{"DataBankName": "ClinicalTrials.gov", "AccessionNumberList": ["NCT04698330"]}], "PublicationTypeList": ["Clinical Trial Protocol", "Journal Article", "Research Support, Non-U.S. Gov't"]}, "MedlineJournalInfo": {"Country": "Switzerland", "MedlineTA": "Front Endocrinol (Lausanne)", "NlmUniqueID": "101555782", "ISSNLinking": "1664-2392"}, "ChemicalList": [{"RegistryNumber": "0", "NameOfSubstance": "Insulin"}, {"RegistryNumber": "0I8Y3P32UF", "NameOfSubstance": "Berberine"}, {"RegistryNumber": "9005-80-5", "NameOfSubstance": "Inulin"}], "MeshHeadingList": [{"QualifierName": [], "DescriptorName": "Adult"}, {"QualifierName": ["therapeutic use"], "DescriptorName": "Berberine"}, {"QualifierName": ["drug therapy"], "DescriptorName": "Diabetes Mellitus, Type 1"}, {"QualifierName": [], "DescriptorName": "Glucose Intolerance"}, {"QualifierName": [], "DescriptorName": "Humans"}, {"QualifierName": [], "DescriptorName": "Insulin"}, {"QualifierName": ["therapeutic use"], "DescriptorName": "Inulin"}, {"QualifierName": [], "DescriptorName": "Latent Autoimmune Diabetes in Adults"}, {"QualifierName": [], "DescriptorName": "Prospective Studies"}, {"QualifierName": [], "DescriptorName": "Quality of Life"}, {"QualifierName": [], "DescriptorName": "Randomized Controlled Trials as Topic"}], "CoiStatement": "The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest."}, "PubmedData": {"ReferenceList": [{"Reference": [{"Citation": "Koufakis T, Karras SN, Zebekakis P, Kotsa K. Results of the First Genome-Wide Association Study of Latent Autoimmune Diabetes in Adults Further Highlight the Need for a Novel Diabetes Classification System. Ann Transl Med (2018) 6(Suppl 2):S102. doi: 10.21037/atm.2018.11.40", "ArticleIdList": ["10.21037/atm.2018.11.40", "PMC6330634", "30740423"]}, {"Citation": "Fourlanos S, Dotta F, Greenbaum CJ, Palmer JP, Rolandsson O, Colman PG, et al. . Latent Autoimmune Diabetes in Adults (LADA) Should be Less Latent. Diabetologia (2005) 48(11):2206\u201312. doi: 10.1007/s00125-005-1960-7", "ArticleIdList": ["10.1007/s00125-005-1960-7", "16193284"]}, {"Citation": "Naik RG, Brooks-Worrell BM, Palmer JP. Latent Autoimmune Diabetes in Adults. J Clin Endocrinol Metab (2009) 94(12):4635\u201344. doi: 10.1210/jc.2009-1120", "ArticleIdList": ["10.1210/jc.2009-1120", "19837918"]}, {"Citation": "Zhou Z, Xiang Y, Ji L, Jia W, Ning G, Huang G, et al. . Frequency, Immunogenetics, and Clinical Characteristics of Latent Autoimmune Diabetes in China (LADA China Study): A Nationwide, Multicenter, Clinic-Based Cross-Sectional Study. Diabetes (2013) 62(2):543\u201350. doi: 10.2337/db12-0207", "ArticleIdList": ["10.2337/db12-0207", "PMC3554388", "23086039"]}, {"Citation": "Hawa MI, Kolb H, Schloot N, Beyan H, Paschou SA, Buzzetti R, et al. . Adult-Onset Autoimmune Diabetes in Europe is Prevalent With a Broad Clinical Phenotype: Action LADA 7. Diabetes Care (2013) 36(4):908\u201313. doi: 10.2337/dc12-0931", "ArticleIdList": ["10.2337/dc12-0931", "PMC3609504", "23248199"]}, {"Citation": "Carlsson S. Etiology and Pathogenesis of Latent Autoimmune Diabetes in Adults (LADA) Compared to Type 2 Diabetes. Front Physiol (2019) 10:320. doi: 10.3389/fphys.2019.00320", "ArticleIdList": ["10.3389/fphys.2019.00320", "PMC6444059", "30971952"]}, {"Citation": "Leslie RD, Williams R, Pozzilli P. Clinical Review: Type 1 Diabetes and Latent Autoimmune Diabetes in Adults: One End of the Rainbow. J Clin Endocrinol Metab (2006) 91(5):1654\u20139. doi: 10.1210/jc.2005-1623", "ArticleIdList": ["10.1210/jc.2005-1623", "16478821"]}, {"Citation": "Pozzilli P, Di Mario U. Autoimmune Diabetes Not Requiring Insulin at Diagnosis (Latent Autoimmune Diabetes of the Adult): Definition, Characterization, and Potential Prevention. Diabetes Care (2001) 24(8):1460\u20137. doi: 10.2337/diacare.24.8.1460", "ArticleIdList": ["10.2337/diacare.24.8.1460", "11473087"]}, {"Citation": "Mishra R, Hodge KM, Cousminer DL, Leslie RD, Grant SFA. A Global Perspective of Latent Autoimmune Diabetes in Adults. Trends Endocrinol Metab (2018) 29(9):638\u201350. doi: 10.1016/j.tem.2018.07.001", "ArticleIdList": ["10.1016/j.tem.2018.07.001", "30041834"]}, {"Citation": "Buzzetti R, Zampetti S, Maddaloni E. Adult-Onset Autoimmune Diabetes: Current Knowledge and Implications for Management. Nat Rev Endocrinol (2017) 13(11):674\u201386. doi: 10.1038/nrendo.2017.99", "ArticleIdList": ["10.1038/nrendo.2017.99", "28885622"]}, {"Citation": "Buzzetti R, Tuomi T, Mauricio D, Pietropaolo M, Zhou Z, Pozzilli P, et al. . Management of Latent Autoimmune Diabetes in Adults: A Consensus Statement From an International Expert Panel. Diabetes (2020) 69(10):2037\u201347. doi: 10.2337/dbi20-0017", "ArticleIdList": ["10.2337/dbi20-0017", "PMC7809717", "32847960"]}, {"Citation": "Brophy S, Davies H, Mannan S, Brunt H, Williams R. Interventions for Latent Autoimmune Diabetes (LADA) in Adults. Cochrane Database Syst Rev (2011) 2011(9):Cd006165. doi: 10.1002/14651858.CD006165.pub3", "ArticleIdList": ["10.1002/14651858.CD006165.pub3", "PMC6486159", "21901702"]}, {"Citation": "Zaharia OP, Bobrov P, Strassburger K, B\u00f3dis K, Karusheva Y, Scholz M, et al. . Metabolic Characteristics of Recently Diagnosed Adult-Onset Autoimmune Diabetes Mellitus. J Clin Endocrinol Metab (2018) 103(2):429\u201337. doi: 10.1210/jc.2017-01706", "ArticleIdList": ["10.1210/jc.2017-01706", "29220505"]}, {"Citation": "Hawa MI, Buchan AP, Ola T, Wun CC, DeMicco DA, Bao W, et al. . LADA and CARDS: A Prospective Study of Clinical Outcome in Established Adult-Onset Autoimmune Diabetes. Diabetes Care (2014) 37(6):1643\u20139. doi: 10.2337/dc13-2383", "ArticleIdList": ["10.2337/dc13-2383", "24722498"]}, {"Citation": "Roh MO, Jung CH, Kim BY, Mok JO, Kim CH. The Prevalence and Characteristics of Latent Autoimmune Diabetes in Adults (LADA) and its Relation With Chronic Complications in a Clinical Department of a University Hospital in Korea. Acta Diabetol (2013) 50(2):129\u201334. doi: 10.1007/s00592-010-0228-y", "ArticleIdList": ["10.1007/s00592-010-0228-y", "20953640"]}, {"Citation": "Myhill P, Davis WA, Bruce DG, Mackay IR, Zimmet P, Davis TM. Chronic Complications and Mortality in Community-Based Patients With Latent Autoimmune Diabetes in Adults: The Fremantle Diabetes Study. Diabetes Med (2008) 25(10):1245\u201350. doi: 10.1111/j.1464-5491.2008.02562.x", "ArticleIdList": ["10.1111/j.1464-5491.2008.02562.x", "19046207"]}, {"Citation": "Xu X, Yi H, Wu J, Kuang T, Zhang J, Li Q, et al. . Therapeutic Effect of Berberine on Metabolic Diseases: Both Pharmacological Data and Clinical Evidence. BioMed Pharmacother (2021) 133:110984. doi: 10.1016/j.biopha.2020.110984", "ArticleIdList": ["10.1016/j.biopha.2020.110984", "33186794"]}, {"Citation": "Wang Y, Liu H, Zheng M, Yang Y, Ren H, Kong Y, et al. . Berberine Slows the Progression of Prediabetes to Diabetes in Zucker Diabetic Fatty Rats by Enhancing Intestinal Secretion of Glucagon-Like Peptide-2 and Improving the Gut Microbiota. Front Endocrinol (Lausanne) (2021) 12:609134. doi: 10.3389/fendo.2021.609134", "ArticleIdList": ["10.3389/fendo.2021.609134", "PMC8138858", "34025574"]}, {"Citation": "Yao Y, Chen H, Yan L, Wang W, Wang D. Berberine Alleviates Type 2 Diabetic Symptoms by Altering Gut Microbiota and Reducing Aromatic Amino Acids. BioMed Pharmacother (2020) 131:110669. doi: 10.1016/j.biopha.2020.110669", "ArticleIdList": ["10.1016/j.biopha.2020.110669", "32937246"]}, {"Citation": "Gong J, Hu M, Huang Z, Fang K, Wang D, Chen Q, et al. . Berberine Attenuates Intestinal Mucosal Barrier Dysfunction in Type 2 Diabetic Rats. Front Pharmacol (2017) 8:42. doi: 10.3389/fphar.2017.00042", "ArticleIdList": ["10.3389/fphar.2017.00042", "PMC5290458", "28217099"]}, {"Citation": "Yin J, Xing H, Ye J. Efficacy of Berberine in Patients With Type 2 Diabetes Mellitus. Metabolism (2008) 57(5):712\u20137. doi: 10.1016/j.metabol.2008.01.013", "ArticleIdList": ["10.1016/j.metabol.2008.01.013", "PMC2410097", "18442638"]}, {"Citation": "Ye Y, Liu X, Wu N, Han Y, Wang J, Yu Y, et al. . Efficacy and Safety of Berberine Alone for Several Metabolic Disorders: A Systematic Review and Meta-Analysis of Randomized Clinical Trials. Front Pharmacol (2021) 12:653887. doi: 10.3389/fphar.2021.653887", "ArticleIdList": ["10.3389/fphar.2021.653887", "PMC8107691", "33981233"]}, {"Citation": "Dehghan P, Pourghassem Gargari B, Asghari Jafar-abadi M. Oligofructose-Enriched Inulin Improves Some Inflammatory Markers and Metabolic Endotoxemia in Women With Type 2 Diabetes Mellitus: A Randomized Controlled Clinical Trial. Nutrition (2014) 30(4):418\u201323. doi: 10.1016/j.nut.2013.09.005", "ArticleIdList": ["10.1016/j.nut.2013.09.005", "24332524"]}, {"Citation": "Ho J, Nicolucci AC, Virtanen H, Schick A, Meddings J, Reimer RA, et al. . Effect of Prebiotic on Microbiota, Intestinal Permeability, and Glycemic Control in Children With Type 1 Diabetes. J Clin Endocrinol Metab (2019) 104(10):4427\u201340. doi: 10.1210/jc.2019-00481", "ArticleIdList": ["10.1210/jc.2019-00481", "31188437"]}, {"Citation": "Li CN, Wang X, Lei L, Liu MZ, Li RC, Sun SJ, et al. . Berberine Combined With Stachyose Induces Better Glycometabolism Than Berberine Alone Through Modulating Gut Microbiota and Fecal Metabolomics in Diabetic Mice. Phytother Res (2020) 34(5):1166\u201374. doi: 10.1002/ptr.6588", "ArticleIdList": ["10.1002/ptr.6588", "PMC7216932", "31833107"]}, {"Citation": "Cao H, Li C, Lei L, Wang X, Liu S, Liu Q, et al. . Stachyose Improves the Effects of Berberine on Glucose Metabolism by Regulating Intestinal Microbiota and Short-Chain Fatty Acids in Spontaneous Type 2 Diabetic KKAy Mice. Front Pharmacol (2020) 11:578943. doi: 10.3389/fphar.2020.578943", "ArticleIdList": ["10.3389/fphar.2020.578943", "PMC7642818", "33192521"]}, {"Citation": "Maddaloni E, Coleman RL, Pozzilli P, Holman RR. Long-Term Risk of Cardiovascular Disease in Individuals With Latent Autoimmune Diabetes in Adults (UKPDS 85). Diabetes Obes Metab (2019) 21(9):2115\u201322. doi: 10.1111/dom.13788", "ArticleIdList": ["10.1111/dom.13788", "31099472"]}, {"Citation": "Maddaloni E, Coleman RL, Agbaje O, Buzzetti R, Holman RR. Time-Varying Risk of Microvascular Complications in Latent Autoimmune Diabetes of Adulthood Compared With Type 2 Diabetes in Adults: A Post-Hoc Analysis of the UK Prospective Diabetes Study 30-Year Follow-Up Data (UKPDS 86). Lancet Diabetes Endocrinol (2020) 8(3):206\u201315. doi: 10.1016/S2213-8587(20)30003-6", "ArticleIdList": ["10.1016/S2213-8587(20)30003-6", "32032540"]}, {"Citation": "Maddaloni E, Moretti C, Del Toro R, Sterpetti S, Ievolella MV, Arnesano G, et al. . Risk of Cardiac Autonomic Neuropathy in Latent Autoimmune Diabetes in Adults is Similar to Type 1 Diabetes and Lower Compared to Type 2 Diabetes: A Cross-Sectional Study. Diabetes Med (2021) 38(2):e14455. doi: 10.1111/dme.14455", "ArticleIdList": ["10.1111/dme.14455", "33170958"]}, {"Citation": "Wang S, Ren H, Zhong H, Zhao X, Li C, Ma J, et al. . Combined Berberine and Probiotic Treatment as an Effective Regimen for Improving Postprandial Hyperlipidemia in Type 2 Diabetes Patients: A Double Blinded Placebo Controlled Randomized Study. Gut Microbes (2022) 14(1):2003176. doi: 10.1080/19490976.2021.2003176", "ArticleIdList": ["10.1080/19490976.2021.2003176", "PMC8726654", "34923903"]}, {"Citation": "Zhang Y, Gu Y, Ren H, Wang S, Zhong H, Zhao X, et al. . Gut Microbiome-Related Effects of Berberine and Probiotics on Type 2 Diabetes (the PREMOTE Study). Nat Commun (2020) 11(1):5015. doi: 10.1038/s41467-020-18414-8", "ArticleIdList": ["10.1038/s41467-020-18414-8", "PMC7538905", "33024120"]}, {"Citation": "Zhu L, Han J, Yuan R, Xue L, Pang W. Berberine Ameliorates Diabetic Nephropathy by Inhibiting TLR4/NF-\u03bab Pathway. Biol Res (2018) 51(1):9. doi: 10.1186/s40659-018-0157-8", "ArticleIdList": ["10.1186/s40659-018-0157-8", "PMC5878418", "29604956"]}, {"Citation": "Zhang M, Zhang Y, Xiao D, Zhang J, Wang X, Guan F, et al. . Highly Bioavailable Berberine Formulation Ameliorates Diabetic Nephropathy Through the Inhibition of Glomerular Mesangial Matrix Expansion and the Activation of Autophagy. Eur J Pharmacol (2020) 873:172955. doi: 10.1016/j.ejphar.2020.172955", "ArticleIdList": ["10.1016/j.ejphar.2020.172955", "32001218"]}, {"Citation": "Wang N, Zhang C, Xu Y, Tan HY, Chen H, Feng Y. Berberine Improves Insulin-Induced Diabetic Retinopathy Through Exclusively Suppressing Akt/mTOR-Mediated HIF-1\u03b1/VEGF Activation in Retina Endothelial Cells. Int J Biol Sci (2021) 17(15):4316\u201326. doi: 10.7150/ijbs.62868", "ArticleIdList": ["10.7150/ijbs.62868", "PMC8579442", "34803500"]}, {"Citation": "Wang N, Wang L, Zhang C, Tan HY, Zhang Y, Feng Y. Berberine Suppresses Advanced Glycation End Products-Associated Diabetic Retinopathy in Hyperglycemic Mice. Clin Transl Med (2021) 11(11):e569. doi: 10.1002/ctm2.569", "ArticleIdList": ["10.1002/ctm2.569", "PMC8567055", "34841704"]}, {"Citation": "Chang W, Zhang M, Meng Z, Yu Y, Yao F, Hatch GM, et al. . Berberine Treatment Prevents Cardiac Dysfunction and Remodeling Through Activation of 5'-Adenosine Monophosphate-Activated Protein Kinase in Type 2 Diabetic Rats and in Palmitate-Induced Hypertrophic H9c2 Cells. Eur J Pharmacol (2015) 769:55\u201363. doi: 10.1016/j.ejphar.2015.10.043", "ArticleIdList": ["10.1016/j.ejphar.2015.10.043", "26522928"]}, {"Citation": "Li HY, Wang XC, Xu YM, Luo NC, Luo S, Hao XY, et al. . Berberine Improves Diabetic Encephalopathy Through the SIRT1/ER Stress Pathway in Db/Db Mice. Rejuvenation Res (2018) 21(3):200\u20139. doi: 10.1089/rej.2017.1972", "ArticleIdList": ["10.1089/rej.2017.1972", "28782427"]}, {"Citation": "Zhou J, Du X, Long M, Zhang Z, Zhou S, Zhou J, et al. . Neuroprotective Effect of Berberine is Mediated by MAPK Signaling Pathway in Experimental Diabetic Neuropathy in Rats. Eur J Pharmacol (2016) 774:87\u201394. doi: 10.1016/j.ejphar.2016.02.007", "ArticleIdList": ["10.1016/j.ejphar.2016.02.007", "26849937"]}, {"Citation": "Wan X, Guo H, Liang Y, Zhou C, Liu Z, Li K, et al. . The Physiological Functions and Pharmaceutical Applications of Inulin: A Review. Carbohydr Polym (2020) 246:116589. doi: 10.1016/j.carbpol.2020.116589", "ArticleIdList": ["10.1016/j.carbpol.2020.116589", "32747248"]}, {"Citation": "Guarner F. Inulin and Oligofructose: Impact on Intestinal Diseases and Disorders. Br J Nutr (2005) 93 Suppl 1:S61\u20135. doi: 10.1079/BJN20041345", "ArticleIdList": ["10.1079/BJN20041345", "15877897"]}, {"Citation": "D'Onofrio L, Kalteniece A, Ferdousi M, Azmi S, Petropoulos IN, Ponirakis G, et al. . Small Nerve Fiber Damage and Langerhans Cells in Type 1 and Type 2 Diabetes and LADA Measured by Corneal Confocal Microscopy. Invest Ophthalmol Vis Sci (2021) 62(6):5. doi: 10.1167/iovs.62.6.5", "ArticleIdList": ["10.1167/iovs.62.6.5", "PMC8107645", "33944892"]}], "ReferenceList": []}], "History": [{"Year": "2022", "Month": "3", "Day": "7"}, {"Year": "2022", "Month": "5", "Day": "5"}, {"Year": "2022", "Month": "7", "Day": "5", "Hour": "10", "Minute": "26"}, {"Year": "2022", "Month": "7", "Day": "6", "Hour": "6", "Minute": "0"}, {"Year": "2022", "Month": "7", "Day": "7", "Hour": "6", "Minute": "0"}, {"Year": "2022", "Month": "1", "Day": "1"}], "PublicationStatus": "epublish", "ArticleIdList": ["35784546", "PMC9241519", "10.3389/fendo.2022.876657"]}}], "PubmedBookArticle": []}